

PEOPLE



Cadence Pharmaceuticals (San Diego) has named **Scott Byrd** (left) senior vice president and chief commercial officer. He joins Cadence from Eli Lilly, where he held positions of increasing responsibility over the last 17 years—most recently serving as US brand leader for prasugrel. Previously, he was senior director, global brands, cardiovascular and acute care.

“We are very pleased to have Scott join the executive team at Cadence,” comments Ted Schroeder, Cadence president and CEO. “We believe that his extensive sales and marketing background in the acute care area and his pre-launch experience with prasugrel will be a significant asset to Cadence as we prepare to commercialize Acetavance, for which we submitted a new drug application to the FDA in May of this year. Scott’s track record of outstanding commercial leadership will complement the expertise within Cadence as we continue to build the capabilities of our company.”

a director of Neurocrine Biosciences since February 1993 and held various executive positions with Neurocrine, including president and CEO, from February 1993 through January 2008. He currently serves on the boards of directors for Rigel Pharmaceuticals, Vical and Facet Biotech.

Chimerix (Durham, NC, USA) has appointed **Kenneth I. Moch** COO, a newly created position. He brings more than 25 years of experience in managing and financing biomedical technologies, most recently founding Euclidean Life Science Advisors. Previously, Moch was managing director, healthcare investment banking at ThinkEquity Partners. He served as president and CEO of Alteon from 1998 to 2005.

Nuon Therapeutics (San Mateo, CA, USA) has announced today that **Arlene Morris**, president and CEO of Affymax, has been elected chairperson of the company’s board of directors. In addition, Nuon has named **Paulette Dillon** to the position of chief business officer and **Tito Serafini** to the position of CSO.

G. Kirk Raab has been elected chairman of the board of directors of Topica Pharmaceuticals (Palo Alto, CA, USA). Raab was formerly CEO of Genentech and served as the first chairman of the newly created Biotechnology Industry Association from 1993–1995.

Apitope International (Diepenbeek, Belgium) has appointed **Graham Roberts** as development director for therapeutics, with overall responsibility for Apitope’s R&D activities. He joins Apitope from SRA GCD (formerly Constella Group), where he served most recently as global vice president of regulatory affairs and strategic drug development services.

Facet Biotech (Redwood City, CA, USA) has announced the appointment of **Mark Rolfe** as senior vice president and CSO. Rolfe held various positions of increasing responsibility at Millennium: The Takeda Oncology Company, most recently as vice president, oncology discovery.

President Barack Obama has nominated **Francis Collins**, who led the government’s successful effort to sequence the human genome in 2001, to head the US National Institutes of Health (Bethesda, MD, USA). Collins, who resigned last year as director of the National Human Genome Research Institute, would succeed **Raynard Kington**, who has been acting director at the NIH since last fall.

Novavax (Rockville, MD, USA) has announced the appointment of **Stanley Erck** to the company’s board of directors. Erck has more than 25 years of experience in biotech and healthcare, serving most recently as president and CEO of Iomai, which was acquired in 2008 by Intercell. Previously, he was president and CEO of Procept. Erck is also a director of BioCryst Pharmaceuticals, MaxCyte and MdBio Foundation.

MDRNa (Bothell, WA, USA) has named **Peter S. Garcia** CFO and secretary. Most recently, Garcia served as CFO of Nanosys, a privately held nanotechnology company.

Mary Lynne Hedley has been appointed executive vice president of operations and CSO of Abraxis BioScience (Los Angeles). She most recently served as executive vice president of Eisai Corporation of North America after Eisai’s acquisition of MGI Pharma, where she had served as executive vice president and CSO since 2005. Previously, she was a cofounder, president and CEO of Zycos. In addition, Abraxis announced the appointment of **Rick Rodgers** as senior vice president and CFO,

succeeding **David O’Toole**. Rodgers was most recently senior vice president, controller and chief accounting officer of MGI Pharma.

Amgen (Thousand Oaks, CA, USA) has appointed **Rebecca M. Henderson** to the company’s board of directors. She recently joined the faculty at the Harvard Business School, having been the Eastman Kodak LFM Professor of Management at the Massachusetts Institute of Technology Sloan School since 1999, and specializes in technology strategy and the broader strategic problems faced by firms in high technology industries. She has been a director of IDEXX Laboratories since 2003.

Ian A.W. Howes has been named CFO and vice president, corporate development of Akebia Therapeutics (Cincinnati). He joins the company from Serenex, where he held the position of CFO and senior vice president, corporate development. Before that, Howes was CFO and vice president, operations at Paradigm Genetics.

Xcellerex (Marlborough, MA, USA) has named **Jonathan Lieber** CFO. He joins Xcellerex from Altus Pharmaceuticals, where he was senior vice president, CFO and treasurer. Previously, he served as a vice president in SG Cowen’s healthcare investment banking group.

Gary A. Lyons has been named to the board of directors of Poniard Pharmaceuticals (S. San Francisco, CA, USA). He has served as